Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Accumulated Expenses (2019 - 2025)

Avidity Biosciences (RNA) has disclosed Accumulated Expenses for 7 consecutive years, with $157.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses rose 143.28% year-over-year to $157.5 million, compared with a TTM value of $157.5 million through Dec 2025, up 143.28%, and an annual FY2025 reading of $157.5 million, up 143.28% over the prior year.
  • Accumulated Expenses was $157.5 million for Q4 2025 at Avidity Biosciences, up from $137.2 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $157.5 million in Q4 2025 and bottomed at $2.7 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $29.7 million, with a median of $10.1 million recorded in 2021.
  • The sharpest move saw Accumulated Expenses grew 25.17% in 2022, then surged 651.95% in 2025.
  • Year by year, Accumulated Expenses stood at $8.9 million in 2021, then increased by 25.17% to $11.2 million in 2022, then increased by 28.11% to $14.3 million in 2023, then soared by 351.52% to $64.7 million in 2024, then surged by 143.28% to $157.5 million in 2025.
  • Business Quant data shows Accumulated Expenses for RNA at $157.5 million in Q4 2025, $137.2 million in Q3 2025, and $95.2 million in Q2 2025.